73
Participants
Start Date
March 21, 2025
Primary Completion Date
October 22, 2026
Study Completion Date
October 21, 2028
Lonsurf
Trifluridine/tipiracil orally 35 mg/m²/dose (D1-D5 twice daily, D1=D15)
Oxaliplatin
Oxaliplatin intravenous injection 85 mg/m² every 2 weeks (D1=D15)
Panitumumab
Panitumumab intravenous injection 6 mg/kg (D1=D15)
Bevacizumab
Bevacizumab intravenous injection 5 mg/kg (D1=D15)
Trastuzumab
Trastuzumab intravenous injection 4 mg/kg (D1=D15)
Nivolumab
Nivolumab intravenous injection 240 mg (D1=D15)
WITHDRAWN
Centre Georges François Leclerc, Dijon
ACTIVE_NOT_RECRUITING
CHU Jean Minjoz, Besançon
ACTIVE_NOT_RECRUITING
Institut Régional du Cancer de Montpellier - ICM Val d'Aurelle, Montpellier
ACTIVE_NOT_RECRUITING
CH de Saint-Malo, St-Malo
NOT_YET_RECRUITING
CHU Saint-Etienne, Saint-Priest-en-Jarez
NOT_YET_RECRUITING
Institut de Cancérologie de l'Ouest, Angers
ACTIVE_NOT_RECRUITING
Centre Hospitalier de Cholet, Cholet
ACTIVE_NOT_RECRUITING
CHU de REIMS, Reims
RECRUITING
Institut Godinot, Reims
NOT_YET_RECRUITING
Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy
ACTIVE_NOT_RECRUITING
Hôpital Privé Jean Mermoz, Lyon
NOT_YET_RECRUITING
Hospices Civils de Lyon, Pierre-Bénite
ACTIVE_NOT_RECRUITING
Hôpital Saint Louis, Paris
RECRUITING
Hôpital Saint Antoine, Paris
ACTIVE_NOT_RECRUITING
Hôpital Cochin, Paris
ACTIVE_NOT_RECRUITING
Hôpital des Diaconesses Croix Saint Simon, Paris
NOT_YET_RECRUITING
CHU Amiens, Amiens
ACTIVE_NOT_RECRUITING
Institut du Cancer d'Avignon, Avignon
ACTIVE_NOT_RECRUITING
CHU de Poitiers, Poitiers
ACTIVE_NOT_RECRUITING
Hôpital Nord Franche-Comté / Site du Mittan, Trévenans
Servier
INDUSTRY
UNICANCER
OTHER